$HIMS
CANACCORD GENUITY:
TOTAL ADDRESSABLE MARKET IN THE UNITED STATES FOR PEPTIDES -- EXCLUDING GLP-1s -- COULD REACH $20 BILLION AND 7-10 MILLION PEOPLE OVER THE NEXT 3-5 YEARS
🤯🤯🤯
$HIMS APP STORE RANKINGS!
- HERS 6
- RO 11
- HIMS 14
Hims growth is accelerating in Credit Card Sales, Web Traffic, and App Downloads.
Every week it seems they seperate even more from Ro!
Q2 is going to be a fun earnings to cover and can’t wait to stream it once again.
$HIMS timeline:
Feb ’25 — peptide facility
Mar ’26 — Wegovy deal
Apr ’26 — FDA schedules peptide vote
May ’26 — guidance raised to $2.8-3B
Jun ’26 — live in US, UK, AU, JP, CA, DE
Jul 23 — FDA vote
Stock still at $27.
$HIMS - It’s funny to me that people get suddenly very bearish when a ugly red day arrives. It’s not about today. It’s about $HIMS as a company for the upcoming 5-10 years. It’s about changing the healthcare system.
It’s about people who suddenly have an access to fast, professional and affordable healthcare system. It’s about 3million subscribers and counting. It’s about many many catalysts which are on the way. I can continue forever. But I don’t want to.
Be sure: the stock price will follow!
The Wegovy pill was approved in the UK yesterday. Pre-orders for our Juniper customers went live today.
That’s how healthcare should work. Drug manufacturers innovate, and customers don’t have to wait to feel great.
If you’re in the UK, we can’t wait to help you on your weight loss journey. Learn more here: myjuniper.co.uk/
Important info here: news.hims.com/disclaimers/ca…